Over the past week, The Australian has featured articles quoting Australia’s two leading medical technology companies, CSL and Cochlear, calling on the Australian government to deliver consistent R&D Tax incentives after four years of policy review and uncertainty. The article comes at a time when Parliament and the Senate are again considering an R&D Tax Reform bill, which was not enacted as law during a previous attempt following concerns raised by the Senate Economics Committee, largely due to complexity of […]